Efficacy and Safety of Proton Pump Inhibitors (PPIs) Plus Rebamipide for Endoscopic Submucosal Dissection-induced Ulcers: A Meta-analysis
|
|
- Luke Palmer
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Efficacy and Safety of Proton Pump Inhibitors (PPIs) Plus Rebamipide for Endoscopic Submucosal Dissection-induced Ulcers: A Meta-analysis Jun Wang, Xufeng Guo, Chuncui Ye, Shijie Yu, Jixiang Zhang, Jia Song, Zhuo Cao, Jing Wang, Min Liu and Weiguo Dong Abstract Objective To compare the efficacy of proton pump inhibitors (PPIs) with rebamipide versus PPIs alone for the treatment of ulcers after endoscopic submucosal dissection (ESD). Methods PubMed, Web of Science, Medline, Embase, the Cochrane Central Register of Controlled Trials and China Naitonal Knowledge Infrastructure were searched up to the end of October 2013 in order to identify all randomized controlled trials reporting the effects of PPIs plus rebamipide on healing ulcers after ESD. The outcome measurement was complete ulcer healing. Results A total of six studies involving 724 patients were included. The pooled data suggested a significantly higher rate of ulcer healing after endoscopic therapy among patients treated with PPIs plus rebamipide than among those treated with PPIs alone [odds ratio (OR)=2.40, 95% confidence interval (CI): ]. The subgroup analysis showed PPI plus rebamipide therapy to be more effective in healing ESD-induced ulcers than treatment with PPIs alone after both four (OR=2.22, 95%CI: ) and eight weeks of treatment (OR=3.19, 95%CI: ). In addition, the combination therapy was found to be significantly more effective than the use of PPIs alone for all ESD ulcers greater than 20 mm in size (OR=4.77, 95%CI: ). There were no significant differences between the treatment groups with regard to ulcer location (low, middle or upper stomach) or the presence of absence of H. pylori infection. No serious adverse events were observed in either group. Conclusion The results of this meta-analysis suggest that treatment with PPIs plus rebamipide is superior to PPI monotherapy for healing ESD-induced ulcers over four weeks, particularly large ulcers. However, more well-designed trials are needed to confirm these findings. Key words: endoscopic submucosal dissection, rebamipide, proton pump inhibitor, meta-analysis (Intern Med 53: , 2014) () Introduction Endoscopic submucosal dissection (ESD) is a minimally invasive treatment for gastric adenoma or early gastric cancer. ESD enables the en bloc resection of gastric lesions, regardless of size or location. The ESD technique can be used to acquire a more accurate histopathological diagnosis relative to that obtained with piecemeal endoscopic resection and may also improve the patient s subsequent quality of life compared to surgery (1). However, ESD is associated with the occurrence of larger, deeper ulcers after the procedure. Proton-pump inhibitors (PPIs) are the most effective medications for treating ESD-induced ulcers. However, some studies have shown that PPI monotherapy does not result in sufficient healing of ESD-induced ulcers within four weeks (2). Rebamipide is a mucosal protective drug for the treatment of ulcers developed in Japan that is widely prescribed in Asian nations (3). Many clinical and experimental trials Department of Gastroenterology, Renmin Hospital of Wuhan University, China Received for publication November 19, 2013; Accepted for publication January 5, 2014 Correspondence to Dr. Weiguo Dong, dwg@whu.edu.cn 1243
2 have indicated that rebamipide therapy accelerates ulcer healing. In a multicenter randomized controlled trials (RCT), rebamipide (Mucosta, Otsuka Pharmaceutical, Tokyo, Japan) was reported to be efficacious for treating large gastric ulcers following Helicobacter pylori eradication (4). Another recent placebo-controlled trial also found that rebamipide is as effective as omeprazole in treating H. pylori-positive gastric ulcers after eradication (5). In randomized controlled studies, rebamipide has been found to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers, accelerate gastric ulcer healing and suppress mucosal inflammation in patients with chronic erosive gastritis (6, 7). Recently, several studies (8-14) have examined the efficacy of rebamipide and PPI combination therapy for the treatment of ESD-induced ulcers. However, there is currently no consensus regarding the optimal treatment duration or drug regimen. Therefore, we conducted a meta-analysis of published data in order to evaluate the efficacy of PPI plus rebamipide therapy for successfully treating ESD-induced ulcers. Search strategy Materials and Methods A literature search was conducted using PubMed, Web of Science, Medline, Embase, the Cochrane Central Register of Controlled Trials and China Naitonal Knowledge Infrastructure up to October 2013 without language restrictions. Relevant RCTs were identified using the following terms: endoscopic submucosal dissection or ESD, proton pump inhibitor or PPI and rebamipide. The search was restricted to human subjects. Additional studies were identified using a hand search of references of original or review articles and international conferences on this topic, primarily including Asian Pacific Digestive Week, United European Gastroenterology Week and American Gastroenterological Association Digestive Disease Week. Inclusion and exclusion criteria Studies were included if they met the following criteria: (1) randomized, controlled human trials with a parallel design, (2) including a comparison of PPI plus rebamipide therapy with PPI monotherapy for healing ESD-induced ulcers, (3) presenting the detailed outcomes of cases and control groups or including such data for calculation in the article text. Meanwhile, the major exclusion criteria were: (1) an unclear study population or trial size, (2) a non-rct, qualitative study or study without extractable data, (3) the administration of rebamipide in the control arm and (4) case reports, editorials, commentaries, reviews or abstracts only. Data extraction and quality assessment Two investigators independently extracted the data and reached a consensus for all items. If the investigators generated different results, they checked the data again and had a discussion in order to reach an agreement. If they were unable to reach an agreement, an expert was invited to join the discussion. Data extracted from the selected articles included the first author s name, year of publication, country of origin, age, gender, patients in the two groups, arms of treatment, medication duration, Helicobacter pylori (Hp) positivity, lesion size, tumor location and endpoints. The ulcer stage was classified using the Sakita-Fukutomi classification system (15): active (A1, A2), healing (H1, H2) and scaring (S1, S2). S-stage was defined as healing of an artificial ulcer. A quality assessment was performed using the scale described by Jadad et al. (16). In this scale, the scores range from 1 to 5, with a higher score indicating higher quality. The scores are based on the method of randomization, level of blinding, concealment of allocation and the use of complete accounting of all randomized patients. We considered RCTs with a score greater than 3 to be high quality. Statistical analysis A meta-analysis was performed using the Cochrane Collaboration RevMan 5.2 and STATA package version The efficacy of PPI plus rebamipide therapy compared with PPI therapy alone for the treatment of ESD-induced ulcers was estimated for each study using the odds ratio (OR) and 95% confidence interval (95%CI). The χ 2 -test-based Q statistic test was performed to assess the between-study heterogeneity (17). We also quantified the effect heterogeneity accordingtothei 2 test. When a significant Q test (p<0.05) or I 2 >50% indicated heterogeneity across studies, the random effects model was used (18); otherwise, the fixed effects model was used (19). The subgroup analyses were performed considering four- and eight-week durations of treatment. An analysis of sensitivity was performed in order to evaluate the stability of the results. Finally, potential publication bias was investigated using Begg s funnel plot and Egger s regression test (20, 21). A p value of <0.05 was regarded as being statistically significant. Study characteristics Results A total of 310 citations were identified in the search. According to the inclusion criteria, seven studies (8-14) with a full text were included in the meta-analysis. Among these seven publications, we excluded one study (14) because the control arm of patients also received rebamipide. Therefore, six eligible RCTs, including 724 patients, were finally included. The characteristics of the selected studies are summarized in Table. Of the six eligible studies, five were from Japan (8-11, 13, 14), and one was from Korea (12). The quality assessment of the included studies was performed using the Jadad score. No trials met all quality measurements; however, all scores were greater than 3, thus indicating a high quality. 1244
3 Table. Characteristics of the Included Studies Reference Year Country Age, mean±sd Gender Patients Interventions Dose Duration Endpoints Quality year (male/female) scores Japan 69.5(52-85) a 30/12 42 PPI omeprazole 20mg/day, lansoprazole 30mg/day, or rabeprazole 10mg/day 71(45-87) 30/15 45 PPI+rebamipide PPI+100mg rebamipide 3 times/day 28d (1) ulcer healing Japan 69±7 24/7 31 PPI omeprazole 20mg/day 56d (1) ulcer healing (2) the effect with a dissection size greater than 40mm 4 68±7 21/9 30 PPI+rebamipide PPI+300mg rebamipide/day (2) the ulcer residual ratio (3) a comparison of the gastric regions of the resection areas Japan 73(57-82) 24/7 31 PPI rabeprazole 10mg/day 28d (1) the ulcer stage 4 73(50-87) 20/11 31 PPI+rebamipide PPI+100mg rebamipide 3 times/day Japan 70.8±9.0 68/17 85 PPI omeprazole 20mg/day, or lansoprazole 30mg/day 70.0±9.0 66/19 85 PPI+rebamipide PPI+300mg rebamipide/day (2) subclass analysis according to the resected specimen size 28-42d (1) ulcer healing 4 (2) the effects of rebamipide according to the artificial ulcer size Korea 64.9± /44* 129 PPI pantoprazole 40mg/day 28d (1) the ulcer reduction rate ± / PPI+rebamipide PPI+100mg rebamipide 3 times/day (2) change of the ulcer stage and quality of ulcer healing Japan 70±7.8 36/9 44 PPI lansoprazole 30mg/day 28/56d (1) ulcer healing 4 67±8.0 31/14 45 Rebamipide lansoprazole 30mg/day, 5d; then 300mg rebamipide, three times a day (2) the ulcer reduction ratio according to the ulcer location Figure 1. Forest plot comparing treatment with PPIs plus rebamipide with PPI monotherapy for ESD-induced ulcers in terms of the overall healing rate Quantitative data synthesis Outcomes The trials with available data for ESD-induced ulcer healing included 362 patients who received PPI plus rebamipide therapy for the treatment of iatrogenic ulcers after endoscopic therapy and 362 control subjects who received PPI monotherapy. There was no statistical heterogeneity among the included studies (I 2 =22%, p=0.27); therefore, the fixedeffects model was used. The estimated pooled data showed a significantly higher rate of ulcer healing after endoscopic therapy in the PPI plus rebamipide group than in the PPI alone group (OR=2.40, 95%CI: ) (Fig. 1). In the subgroup analysis of the duration of treatment, we found that treatment with PPIs plus rebamipide was more effective in healing ESD-induced ulcers than PPI monotherapy over both four- (OR=2.22, 95%CI: ) and eight-week durations of treatment (OR=3.19, 95%CI: ) (Fig. 2). The sensitivity analysis performed using sequential excluding of one trial at a time did not alter the results. Two trials (9, 13) with available data for the location of resection included 165 patients who received treatment with PPIs plus rebamipide and 163 control subjects who received PPI monotherapy. The rate of ulcer healing was not significantly different between the treatment groups. Two trials (12, 13) with available data for H. pylori infection included 184 patients who received treatment with PPIs plus rebamipide and 186 control subjects who received PPI monotherapy. We also detected no significant differences between the treatment groups in this analysis. Two trials (8, 10) with available data for the specimen size included 74 patients who received treatment with PPIs plus rebamipide and 72 control subjects who received PPI monotherapy. The pooled data suggested a significantly higher rate of ulcer healing after endoscopic therapy in the PPI plus rebamipide group than in the PPI alone group for both a specimen size between mm (OR=3.58, 95%CI: 1245
4 Figure 2. Forest plot comparing treatment with PPIs plus rebamipide with PPI monotherapy for healing of ESD-induced ulcers in terms of the duration of treatment Figure 3. Forest plot comparing treatment with PPIs plus rebamipide with PPI monotherapy for healing of ESD-induced ulcers in terms of the specimen size ) and >40 mm (OR=12.66, 95%CI: ) (Fig. 3). Adverse events Three trials (9, 10, 13) reported adverse events. Only one of these studies reported serious adverse events in the two groups: the study by Fujiwara et al. reported that one patient in the PPI group experienced bleeding from a post-esd artificial ulcer. Publication bias Begg s funnel plot and Egger s test were performed to assess the potential publication bias in the available literature. The shape of the funnel plots did not reveal any evidence of asymmetry (Fig. 4). Egger s test also showed that there was no statistical significance for the evaluation of publication bias (p=0.143). Discussion ESD was developed in Japan to enable the en bloc complete resection of superficial gastrointestinal neoplasms, regardless of the size or location of the lesions. ESD results in the creation of larger artificial ulcers. Although PPIs are the 1246
5 Begg's funnel plot with pseudo 95% confidence limits 2 1 logor s.e. of: logor Figure 4. Begg s funnel plot to assess publication bias standard treatment for ESD-induced ulcers and bleeding after ESD, Fujiwara et al. (9) reported that treatment with PPIs and acid-suppressive agents alone has limited effects in patients with a low level acid secretion, such as those with severe atrophic conditions in the gastric mucosa. Terano et al. (4) reported that, in their study, seven weeks of rebamipide treatment without acid-suppressive agents promoted gastric ulcer healing after eradication therapy compared with a placebo. In addition, in patients with little acid secretion (such as those with severe atrophic gastritis), the suppression of acid is not a major factor in ulcer healing. Therefore, it remains insufficient to attempt to successfully treat ulcers using PPIs alone, and the use of combination therapy is therefore needed. In this study, we conducted a meta-analysis to explore the efficacy of treatment with PPIs plus rebamipide for healing ESD-induced ulcers. The results conclusively showed that PPI plus rebamipide therapy is superior to PPI monotherapy for healing ESD-induced ulcers, particularly large ulcers (size >20 mm). In addition, no episodes of ulcer bleeding or complications related to the drugs used after ESD were observed in any of the study subjects. These results can be explained by the regulatory effects of rebamipide on the inflammatory process. Several studies have been found that rebamipide promotes ulcer healing by increasing the levels of cytoprotective prostaglandins (22), epidermal growth factor (23) and nitric oxide (24) and decreasing the levels of oxygen free radicals (25). These actions increase the gastric mucosal blood flow at the ulcer margin, an important factor for ulcer healing, and accelerate the mucosal or submucosal reconstruction of damaged structures (24, 26). A recent animal study suggested that treatment with rebamipide enhances the quality of ulcer healing by increasing the level of prostaglandin E2 and decreasing the levels of interleukin-8 and malondialdehyde (27). Previous studies have also reported that ulcer healing is associated with both the lesion size and tumor location. In this meta-analysis, two trials evaluated the degree of ulcer healing with respect to the lesion size and tumor location, and we found a significantly higher rate of ulcer healing after endoscopic therapy in the PPI plus rebamipide group than in the PPI alone group for both a lesion size between mm and >40 mm (particularly the latter). However, there were no significant differences between the treatment groups with regard to ulcer location (low, middle or upper stomach). Although Hp infection is generally considered to be a causal factor in the pathogenesis of peptic ulcers, a few studies found that the Hp status does not affect the rate of ulcer healing after ESD (28). Similarly, in this study, the pooled data suggested there were no significant differences between the treatment groups. In addition, three trials reported adverse events, and no episodes of ulcer bleeding or complications related to the drugs used after ESD were observed in the two groups. However, because only a few trials were included, these results should therefore be interpreted with caution, and more studies are needed. It would be difficult to interpret the results if significant heterogeneity was present. However, we did not find any obvious heterogeneity or publish bias across the studies in this meta-analysis. In addition, the sensitivity analysis using sequential excluding of one trial at a time did not alter the results, thus indicating that our results were statistically robust. However, some limitations of this meta-analysis should be addressed. First, the quality of the included RCTs was relatively low, as no trials met all quality measurements, which may have influenced the results. Second, the trials were carried out with less consistency of outcomes, indicating the insufficiency of combinable studies, which limits the subgroup analyses, detection of heterogeneity and evaluation of bias. Third, the use of various types of PPI medications and diverse PPI regimes may have produced a small amount of bias. 1247
6 In conclusion, this meta-analysis showed that treatment with PPIs plus rebamipide is superior to PPI monotherapy for healing ESD-induced ulcers over a period of four weeks, particularly regarding large ulcers. However, more welldesigned trials are needed to confirm these findings. The authors state that they have no Conflict of Interest (COI). References 1. Yamamoto H. Endoscopic submucosal dissection--current success and future directions. Nat Rev Gastroenterol Hepatol 9: , Asakuma Y, Kudo M, Matsui S, et al. Comparison of an ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers in early gastric cancer: prospective randomized study. Hepatogastroenterology 56: , Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 4: , Terano A, Arakawa T, Sugiyama T, et al. Rebamipide, a gastroprotective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobactor pylori in Japanese population: a randomized, double-blind, placebocontrolled trial. J Gastroenterol 42: , Song KH, Lee YC, Fan DM, et al. Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study. Digestion 84: , Park SH, Cho CS, Lee OY, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-storm STUDY. J Clin Biochem Nutr 40: , Du T, Li Z, Zhan X, et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci 53: , Araki H, Kato T, Onogi F, et al. Combination of proton pump inhibitor and rebamipide, a free radical scavenger, promotes artificial ulcer healing after endoscopic submucosal dissection with dissection size >40 mm. J Clin Biochem Nutr 51: , Fujiwara S, Morita Y, Toyonaga T, et al. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 46: , Kato T, Araki H, Onogi F, et al. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection--a randomized controlled study. J Gastroenterol 45: , Kobayashi M, Takeuchi M, Hashimoto S, et al. Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide. Dig Dis Sci 57: , Shin WG, Kim SJ, Choi MH, et al. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc 75: , Takayama M, Matsui S, Kawasaki M, et al. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol 19: , Bunno M, Gouda K, Yamahara K, Kawaguchi M. A case-control study of esomeprazole plus rebamipide vs. omeprazole plus rebamipide on post-esd gastric ulcers. Jpn Clin Med 4: 7-13, Sakita T, Fukushima H. Endoscopic diagnosis. In: I, Junishityoshuyo No Subete. Yoshitoshi Y, Ed. Nankodo, Tokyo, 1971: (in Japanese). 16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 127: , DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 7: , Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: , Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50: , Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 315: , Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38: , Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 43: 90S-98S, Takaishi O, Arakawa T, Yamasaki K, et al. Protective effect of rebamipide against ammonia-induced gastric mucosal lesions. Dig Dis Sci 43: 78S-82S, Naito Y, Yoshikawa T, Tanigawa T, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18: , Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 49: , Qi Z, Jie L, Haixia C, Xiaoying Z. Effect of rebamipide on quality of peptic ulcer healing in rat. Dig Dis Sci 54: , Kakushima N, Fujishiro M, Yahagi N, Kodashima S, Nakamura M, Omata M. Helicobacter pylori status and the extent of gastric atrophy do not affect ulcer healing after endoscopic submucosal dissection. J Gastroenterol Hepatol 21: , The Japanese Society of Internal Medicine
Database of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationToshihiro Nishizawa 1,2, Hidekazu Suzuki 2, Teppei Akimoto 1,3, Tadateru Maehata 1, Toshio Morizane 4, Takanori Kanai 2 and Naohisa Yahagi 1
Review Article Effects of preoperative proton pump inhibitor administration on bleeding after gastric endoscopic submucosal dissection: A systematic review and meta-analysis United European Gastroenterology
More informationEffective healing of endoscopic submucosal dissection-induced ulcers by a single week of proton pump inhibitor treatment: a retrospective study
Kajiura et al. BMC Research Notes (2015) 8:150 DOI 10.1186/s13104-015-1111-2 RESEARCH ARTICLE Open Access Effective healing of endoscopic submucosal dissection-induced ulcers by a single week of proton
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationImage Analysis of Magnifying Endoscopy for Differentiation between Early Gastric Cancers and Gastric Erosions
Showa Univ J Med Sci 29 3, 297 306, September 2017 Original Image Analysis of Magnifying Endoscopy for Differentiation between Early Gastric Cancers and Gastric Erosions Shotaro HANAMURA, Kuniyo GOMI,
More informationPrognostic analysis of gastric mucosal dysplasia after endoscopic resection: A single-center retrospective study
JBUON 2019; 24(2): 679-685 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Prognostic analysis of gastric mucosal dysplasia after endoscopic resection:
More informationProton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs
ORIGINAL ARTICLE Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs Yuki Sakamoto, Tadashi Shimoyama, Satoru Nakagawa,
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationRelationship between vitamin D (1,25-dihydroxyvitamin D3) receptor gene polymorphisms and primary biliary cirrhosis risk: a meta-analysis
Relationship between vitamin D (1,25-dihydroxyvitamin D3) receptor gene polymorphisms and primary biliary cirrhosis risk: a meta-analysis F. Fang, J. Wang, J. Pan, G.H. Su, L.X. Xu and G. Li Institute
More informationCancerous esophageal stenosis before treatment was significantly correlated to poor prognosis of patients with esophageal cancer: a meta-analysis
Original Article Cancerous before treatment was significantly correlated to poor prognosis of patients with cancer: a meta-analysis Han-Yu Deng 1,2#, Guha Alai 1#, Jun Luo 1#, Gang Li 1, Ze-Guo Zhuo 1,
More informationKorean gastric cancer screening program, algorithms and experience.
Korean gastric cancer screening program, algorithms and experience. Jun Haeng Lee, MD. Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea Today s topics Korean cancer screening
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationAssociation between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis
Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the
More informationIntermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis
Research Original Investigation Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis Hamita Sachar, MD; Keta Vaidya, MD; Loren Laine,
More informationINTRODUCTION ORIGINAL ARTICLE. Sang Gyun Kim 1, Nayoung Kim 2, Sung Kwan Shin 3, In Kyung Sung 4, Su Jin Hong 5 and Hyo-Jin Park 3
ORIGINAL ARTICLE Clin Endosc 2017;50:179-184 https://doi.org/10.5946/ce.2016.031 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant
More informationReview. Key words : asthma, benralizumab, interleukin-5, mepolizumab, reslizumab. Introduction
Showa Univ J Med Sci 30 1, 11 25, March 2018 Review Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma : A Systematic Review and
More informationCorrespondence should be addressed to Tomoari Kamada;
Hindawi Publishing Corporation BioMed Research International Volume 21, Article ID 86146, 8 pages http://dx.doi.org/1.11/21/86146 Clinical Study Rebamipide Improves Chronic Inflammation in the Lesser Curvature
More informationDelayed bleeding and hemorrhage of mucosal defects after gastric endoscopic submucosal dissection on second-look endoscopy
Gastric Cancer (2016) 19:561 567 DOI 10.1007/s10120-015-0507-y ORIGINAL ARTICLE Delayed bleeding and hemorrhage of mucosal defects after gastric endoscopic submucosal dissection on second-look endoscopy
More informationShort-Term Healing Process of Artificial Ulcers after Gastric Endoscopic Submucosal Dissection
Gut and Liver, Vol. 5, No. 3, September 2011, pp. 293-297 ORiginal Article Short-Term Healing Process of Artificial Ulcers after Gastric Endoscopic Submucosal Dissection Osamu Goto*, Mitsuhiro Fujishiro,
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationHelicobacter pylori Eradication in Patients with an Iatrogenic Ulcer after Endoscopic Resection and Peptic Ulcer
ORIGINAL ARTICLE ISSN 1738-3331, https://doi.org/10.7704/kjhugr.2018.18.1.30 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018;18(1):30-37 Helicobacter pylori Eradication in
More informationEndoscopic Submucosal Dissection ESD
Endoscopic Submucosal Dissection ESD Peter Draganov MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Florida Gastrointestinal Cancer Lesion that Can be Treated
More informationSUMMARY INTRODUCTION. Accepted for publication 11 May 2005
Aliment Pharmacol Ther 2005; 22: 169 174. doi: 10.1111/j.1365-2036.2005.02546.x Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements
More informationSecond-Look Endoscopy after Gastric Endoscopic Submucosal Dissection for Reducing Delayed Postoperative Bleeding
Gut and Liver, Vol. 9, No. 1, January 2015, pp. 43-51 ORiginal Article Second-Look Endoscopy after Gastric Endoscopic Submucosal Dissection for Reducing Delayed Postoperative Bleeding Chan Hyuk Park, Jun
More informationProton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This
More informationContinued use of low-dose aspirin may increase risk of bleeding after gastrointestinal endoscopic submucosal dissection: A meta-analysis
Turk J Gastroenterol 2017; 28: 329-36 Gastrointestinal Tract Continued use of low-dose aspirin may increase risk of bleeding after gastrointestinal endoscopic submucosal dissection: A meta-analysis Wei
More informationA systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer
ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 1-10 A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer Theodore Rokkas a, Androniki
More informationMetal versus plastic stents for malignant biliary obstruction: An update meta-analysis
Clinics and Research in Hepatology and Gastroenterology (2013) xxx, xxx xxx Available online at www.sciencedirect.com ORIGINAL ARTICLE Metal versus plastic stents for malignant biliary obstruction: An
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationRelationship between RUNX3 methylation and hepatocellular carcinoma in Asian populations: a systematic review
Relationship between RUNX3 methylation and hepatocellular carcinoma in Asian populations: a systematic review X.X. Lu 1,2 *, L.Q. Zhu 1,2 *, F. Pang 3, W. Sun 1,2, C. Ou 1, Y. Li 1, J. Cao 1 and Y.L. Hu
More informationThe angiotensin-converting enzyme (ACE) I/D polymorphism in Parkinson s disease
4432JRA0010.1177/1470320313494432Journal of the Renin-Angiotensin-Aldosterone SystemSu et al Original Article The angiotensin-converting enzyme (ACE) I/D polymorphism in Parkinson s disease Journal of
More informationEfficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms
Original Article JCBN Journal 0912-0009 1880-5086 the Kyoto, jcbn12-27 10.3164/jcbn.12-27 Original Society Japan of Article Clinical for Free Biochemistry Radical Research and Nutrition Japan Efficacy
More informationAbstract. Background. Aims. Methods. Results
RESEARCH ARTICLE Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis Da Hyun Jung 1, Jie-Hyun Kim 2, Hyun Soo Chung
More informationProton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This
More informationLack of association between IL-6-174G>C polymorphism and lung cancer: a metaanalysis
Lack of association between IL-6-174G>C polymorphism and lung cancer: a metaanalysis Y. Liu, X.L. Song, G.L. Zhang, A.M. Peng, P.F. Fu, P. Li, M. Tan, X. Li, M. Li and C.H. Wang Department of Respiratory
More informationPrevalence of Multiple White and Flat Elevated Lesions in Individuals Undergoing a Medical Checkup
doi: 10.2169/internalmedicine.9808-17 http://internmed.jp ORIGINAL ARTICLE Prevalence of Multiple White and Flat Elevated Lesions in Individuals Undergoing a Medical Checkup Kyoichi Adachi 1, Tomoko Mishiro
More informationDelayed Perforation Occurring after Endoscopic Submucosal Dissection for Early Gastric Cancer
CASE REPORT Clin Endosc 2015;48:251-255 Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.251 Open Access Delayed Perforation Occurring after Endoscopic Submucosal Dissection
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationD DAVID PUBLISHING. 1. Introduction. Maher Mbarki 1, Helen Sklyarova 1, Krystyna Aksentiychuk 1, Ihor Tumak 2 and Eugene Sklyarov 1
Journal of Pharmacy and Pharmacology (2016) 32-36 doi: 10.17265/232-2150/2016.0.011 D DAVID PUBLISHING Plasma Levels of Leukotriene B and Prostaglandin E2 Correlation with Endoscopic Changes after NSAID
More informationMulticenter study of the long-term outcomes of endoscopic submucosal dissection for early gastric cancer in patients 80 years of age or older
Gastric Cancer (2012) 15:70 75 DOI 10.1007/s10120-011-0067-8 ORIGINAL ARTICLE Multicenter study of the long-term outcomes of endoscopic submucosal dissection for early gastric cancer in patients 80 years
More informationBilateral stenting methods for hilar biliary obstructions
RAPID COMMUNICATION Bilateral stenting methods for hilar biliary obstructions Wandong Hong, I Shanxi Chen, II Qihuai Zhu, I Huichun Chen, III Jingye Pan, IV Qingke Huang I* I First Affiliated Hospital
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationOriginal Article Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H.pylori-associated duodenal ulcer
Int J Physiol Pathophysiol Pharmacol 2015;7(3):158-164 www.ijppp.org /ISSN:1944-8171/IJPPP0009907 Original Article Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H.pylori-associated
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationulcer healing role 118 Bicarbonate, prostaglandins in duodenal cytoprotection 235, 236
Subject Index Actin cellular forms 48, 49 epidermal growth factor, cytoskeletal change induction in mucosal repair 22, 23 wound repair 64, 65 polyamine effects on cytoskeleton 49 51 S-Adenosylmethionine
More informationMeta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE
4th International Conference on Sustainable Energy and Environmental Engineering (ICSEEE 2015) Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined
More informationPreventive Efficacy and Safety of Rebamipide in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity
Gut and Liver, Vol. 8, No. 4, July 2014, pp. 371-379 ORiginal Article Preventive Efficacy and Safety of in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity Jeong Ho Kim*,a, Soo-Heon Park*,
More informationEfficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: A systematic review and meta-analysis
e-issn 1643-3750 DOI: 10.12659/MSM.890102 Received: 2013.11.28 Accepted: 2014.02.07 Published: 2014.06.17 Efficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: A systematic
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationRisk factors for non-curative resection of early gastric neoplasms with endoscopic submucosal dissection: Analysis of 1,123 lesions
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1209-1214, 2015 Risk factors for non-curative resection of early gastric neoplasms with endoscopic submucosal dissection: Analysis of 1,123 lesions TATSUYA TOYOKAWA
More informationHow to treat early gastric cancer? Endoscopy
How to treat early gastric cancer? Endoscopy Presented by Pierre H. Deprez Institution Cliniques universitaires Saint-Luc, Brussels Université catholique de Louvain 2 3 4 5 6 Background Diagnostic or therapeutic
More informationEarly and long term outcomes of endoscopic submucosal dissection for early gastric cancer in a large patient series
594 Early and long term outcomes of endoscopic submucosal dissection for early gastric cancer in a large patient series KEN OHNITA 1, HAJIME ISOMOTO 1, SABURO SHIKUWA 2, HIROYUKI YAJIMA 1, HITOMI MINAMI
More informationGastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationResearch Article Meta-Analysis and Systemic Review of Different Reconstruction Methods for Gastric Carcinoma Following Distal Gastrectomy
Cronicon OPEN ACCESS CANCER Research Article Meta-Analysis and Systemic Review of Different Reconstruction Methods for Gastric Carcinoma Following Distal Shuailong Yang, Fangfang Chen, Shuyi Wang, Haibin
More informationEffect of Helicobacter pylori Eradication on Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasm
60 ORIGINAL CONTRIBUTIONS nature publishing group see related editorial on page x Effect of Helicobacter pylori Eradication on Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasm Suh
More informationIs a Second-Look Endoscopy Necessary after Endoscopic Submucosal Dissection for Gastric Neoplasm?
Gut and Liver, Vol. 9, No. 1, January 2015, pp. 52-58 ORiginal Article Is a Second-Look Endoscopy Necessary after Endoscopic Submucosal Dissection for Gastric Neoplasm? Eun Ran Kim*, Jung Ha Kim*, Ki Joo
More informationAssociation of mir-21 with esophageal cancer prognosis: a meta-analysis
Association of mir-21 with esophageal cancer prognosis: a meta-analysis S.-W. Wen 1, Y.-F. Zhang 1, Y. Li 1, Z.-X. Liu 2, H.-L. Lv 1, Z.-H. Li 1, Y.-Z. Xu 1, Y.-G. Zhu 1 and Z.-Q. Tian 1 1 Department of
More informationAssociations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis
Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis D. Zhang 1, Q. Li 2, H.-C. Qu 3, T. Yu 2 and Y.-R. Liu 1 1 College of Basic Medical Science,
More informationThe objective of this systematic review is to assess the impact of migration on the risk of developing gastric cancer.
Review title The effect of migration on gastric cancer risk: A systematic review protocol Reviewers Haejin In, MD, MBA, MPH 1 Marisa Langdon-Embry, MS 2 1 Albert Einstein College of Medicine, haejin.in@einstein.yu.edu
More informationTreatment Strategy for Non-curative Resection of Early Gastric Cancer. Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea
Treatment Strategy for Non-curative Resection of Early Gastric Cancer Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea Classic EMR/ESD data analysis style Endoscopic resection
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Evidence Tables July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May 2005
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationManagement of early gastric cancer with positive horizontal or indeterminable margins after endoscopic submucosal dissection: multicenter survey
Management of early gastric cancer with positive horizontal or indeterminable margins after endoscopic submucosal dissection: multicenter survey Authors Naoki Ishii 1,FumioOmata 1,JunkoFujisaki 2, Toshiaki
More informationContinued versus interrupted aspirin use and bleeding risk after endoscopic submucosal dissection of gastric neoplasms: a meta-analysis
ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-7 Continued versus interrupted aspirin use and bleeding risk after endoscopic submucosal dissection of gastric neoplasms: a meta-analysis Veeravich
More informationPharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network metaanalysis
Xin et al. BMC Gastroenterology (2016) 16:80 DOI 10.1186/s12876-016-0491-7 RESEARCH ARTICLE Open Access Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationIntroduction. Piecemeal EMR (EPMR) Symposium
Symposium Symposium II - Lower GI : Colonoscopy Issues in 2015 Resection of Large Polyps Using Techniques other than Endoscopic Submucosal Dissection: Piecemeal Resection, Underwater Endoscopic Mucosal
More informationUsefulness of the Forrest Classification to Predict Artificial Ulcer Rebleeding during Second-Look Endoscopy after Endoscopic Submucosal Dissection
ORIGINAL ARTICLE Clin Endosc 2016;49:273-281 http://dx.doi.org/10.5946/ce.2015.086 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Usefulness of the Forrest Classification to Predict Artificial
More informationComparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis
open access Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis Bao-Zhu Li, 1,2 Diane Erin Threapleton, 3 Ji-Yao Wang, 4 Jian-Ming
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More informationMeta-analyses: analyses:
Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific
More informationA case of local recurrence and distant metastasis following curative endoscopic submucosal dissection of early gastric cancer
Gastric Cancer (2015) 18:188 192 DOI 10.1007/s10120-014-0341-7 CASE REPORT A case of local recurrence and distant metastasis following curative endoscopic submucosal dissection of early gastric cancer
More informationSupplementary Online Content
Supplementary Online Content Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for highrisk bleeding ulcers: systematic review and meta-analysis. JAMA Intern Med. Published
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationBritish Journal of Nutrition
, page 1 of 6 q The Authors 2011 doi:10.1017/s0007114511003813 Meta-analysis Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis Guogang Li 1, Lan Li 2, Chaohui
More informationData extraction. Specific interventions included in the review Dressings and topical agents in relation to wound healing.
Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds Bradley M, Cullum N, Nelson E A, Petticrew M, Sheldon T, Torgerson D Authors' objectives
More informationClinical Outcomes of Endoscopic Submucosal Dissection in Patients under 40 Years Old with Early Gastric Cancer
ORIGINAL ARTICLE ISSN 1738-3331, http://dx.doi.org/10.7704/kjhugr.2016.16.3.139 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2016;16(3):139-146 Clinical Outcomes of Endoscopic
More informationSystematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy
Systematic review with multiple treatment comparison metaanalysis on interventions for hepatic encephalopathy Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with severe
More informationAlectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
Showa Univ J Med Sci 30 2, 309 315, June 2018 Original Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis Ryo MANABE 1, Koichi ANDO
More informationRelationship of Helicobacter pylori Infection with Gastric Black Spots Shown by Endoscopy
doi: 10.2169/internalmedicine.1751-18 http://internmed.jp ORIGINAL ARTICLE Relationship of Helicobacter pylori Infection with Gastric Black Spots Shown by Endoscopy Kyoichi Adachi 1, Takumi Notsu 1, Tomoko
More informationA. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.
Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine
More informationChoice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias
Technical appendix Choice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias Choice of axis in funnel plots Funnel plots were first used in educational research and psychology,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationThe effect of proton pump inhibitors on the gastric mucosal microenvironment
Original papers The effect of proton pump inhibitors on the gastric mucosal microenvironment Yen-Chun Peng,,, A F, Lan-Ru Huang, A, C, E, Hui-Ching Ho, C, Chi-Sen Chang, C, E, Shou-Wu Lee, E, Ching-Chang
More informationDisclosures. Gastric Intestinal Metaplasia and Early Gastric Cancer: Screening, Surveillance, and Endoscopic Therapy. ASGE Guidelines.
Gastric Intestinal Metaplasia and Early Gastric Cancer: Screening, Surveillance, and Endoscopic Therapy Consultant for: Olympus Medtronic US Endoscopy Disclosures Joo Ha Hwang, MD, PhD Associate Professor
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationDrain versus no-drain after gastrectomy for patients with advanced gastric cancer Student EBM presentations
Drain versus no-drain after gastrectomy for patients with advanced gastric cancer Student EBM presentations Selali Fiamanya & Jawaad Farrukh University of Oxford October 2014 The question Mr X is a 56
More informationStudy selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were eligible for inclusion in the review.
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses Stokman M A, Spijkervet F K, Boezen H M, Schouten J P, Roodenburg J L, de Vries
More informationSupplementary Online Content
Supplementary Online Content Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationProtonix for bleeding
Protonix for bleeding The Borg System is 100 % Protonix for bleeding Dec 17, 2010. The ideal pharmacologic therapy for highrisk patients with acute peptic ulcer bleeding is an IV PPI started immediately
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More information